Title: Long-term Follow-up Results From The Phase 2 Multicenter Study Of Ublituximab (utx), A Novel Glycoengineered Anti-cd20 Mab, In Patients With Rms

被引：0
|
作者：
Fox, E. [1 ]
Shubin, R. [2 ]
Bass, A. [3 ]
Huang, D. [4 ]
Lovett-Racke, A. [5 ]
Weiss, M. S. [6 ]
Bosco, J. [6 ]
Power, S. [6 ]
Mok, K. [6 ]
Wray, S. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Arcadia Neurol Ctr, Arcadia, CA USA
[3] Neurol Ctr San Antonio, San Antonio, TX USA
[4] Ctr Multiple Sclerosis, Westerville, OH USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] TG Therapeut, New York, NY USA
[7] Hope Neurol, Knoxville, TN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P075
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [11] Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis
    Fox, E.
    Lovett-Racke, A.
    Inglese, M.
    Wray, S.
    Racke, M.
    Shubin, R.
    Eubanks, J.
    Su, W.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 407 - 407
  • [12] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
    Fox, Edward
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Cocozza, Sirio
    Shubin, Richard
    Wray, Sibyl
    Weiss, Michael S.
    Bosco, Jenna A.
    Power, Sean A.
    Mok, Koby
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
  • [13] Phase-2 multicenter study results of Ublituximab, a novel glycoengineered antiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)
    Fox, E. J.
    Lovett-Racke, A.
    Inglese, M.
    Shubin, R.
    Twyman, C.
    Eubanks, J.
    Mok, K.
    Su, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 71 - 71
  • [14] 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
    Fox, Edward J.
    Lovett-Racke, Amy
    Wray, Sibyl
    Racke, Michael K.
    Shubin, Richard
    Twyman, Cary
    Eubanks, James
    Su, Wendy
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 23 - 23
  • [15] Final MRI Results At 6 Months From A Phase 2 Multicenter Study Of Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions
    Inglese, Matilde
    Petracca, Maria
    Cocozza, Sirio
    Wray, Sibyl
    Racke, Michael
    Shubin, Richard
    Twyman, Cary
    Su, Wendy
    Eubanks, James
    Mok, Koby
    Weiss, Michael
    Fox, Edward
    NEUROLOGY, 2018, 90
  • [16] UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH CLL AND MCL; RESULTS OF AN ONGOING PHASE II TRIAL
    Sharman, J. P.
    Farber, C. M.
    Mahadevan, D.
    Schreeder, M. T.
    Mackenzie, M.
    Brotherton, M.
    Pauli, E. K.
    Cutter, K.
    Sportelli, P.
    Miskin, H. P.
    O'Connor, O. A.
    HAEMATOLOGICA, 2014, 99 : 326 - 327
  • [17] Study design and patient demographics of the ULTIMATE phase III trials evaluating Ublituximab (UTX), a novel glyco-engineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
    Steinman, L.
    Fox, E.
    Hartung, H. -P.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M.
    Power, S.
    Bosco, J.
    Mok, K.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 523 - 524
  • [18] IDEC-C2B8 anti-CD20 antibody: Results of long-term follow-up of relapsed NHL phase II trial patients
    Maloney, DG
    GrilloLopez, AJ
    Bodkin, D
    White, C
    Foon, K
    Schilder, RJ
    Neidhart, J
    Janakiraman, N
    Waldichuk, C
    Davis, T
    Dallaire, BK
    Royston, I
    Levy, R
    BLOOD, 1995, 86 (10) : 205 - 205
  • [19] Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis
    Steinman, Lawrence
    Fox, Edward
    Hartung, Hans-Peter
    Cree, Bruce
    Alvarez, Enrique
    Qian, Peiqing
    Wray, Sibyl
    Robertson, Derrick
    Huang, Deren
    Selmaj, Krzystof
    Wynn, Daniel
    Weiss, Michael
    Bosco, Jenna
    Power, Sean
    Mok, Koby
    NEUROLOGY, 2020, 94 (15)
  • [20] Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
    Sharman, Jeff P.
    Farber, Charles M.
    Mahadevan, Daruka
    Schreeder, Marshall T.
    Brooks, Heather D.
    Kolibaba, Kathryn S.
    Fanning, Suzanne
    Klein, Leonard
    Greenwald, Daniel R.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Burke, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 412 - 420
12345